{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:21:05Z","timestamp":1794900065576,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of\n                    <jats:italic>MUC16<\/jats:italic>\n                    (CA125),\n                    <jats:italic>MUC4<\/jats:italic>\n                    , and\n                    <jats:italic>KRT24<\/jats:italic>\n                    . This cell state is enriched in metastases, predicted to be highly resistant to\u00a0chemotherapy, and linked with poor survival. We also find enriched expression of\n                    <jats:italic>TM4SF1<\/jats:italic>\n                    , a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro\u00a0and in vivo activity against bladder cancer cell lines in a\n                    <jats:italic>TM4SF1<\/jats:italic>\n                    expression-dependent manner, highlighting its potential as a therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-59888-8","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:02:04Z","timestamp":1750136524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression"],"prefix":"10.1038","volume":"16","author":[{"given":"Heiko","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-8813","authenticated-orcid":false,"given":"Hanbing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Gilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Allegakoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-9537","authenticated-orcid":false,"given":"Kevin L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliana","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynn","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janae","family":"Gayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Stohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-0222","authenticated-orcid":false,"given":"Chien-Kuang","family":"Cornelia Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell V.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-0391","authenticated-orcid":false,"given":"Jonathan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima P.","family":"Porten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-0436","authenticated-orcid":false,"given":"Franklin W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"59888_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo, N. et al. What is the significance of variant histology in urothelial carcinoma?. Eur. Urol. Focus 6, 653\u2013663 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"59888_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part B: Prostate and bladder tumours. Eur. Urol. 70, 106\u2013119 (2016).","journal-title":"Eur. Urol."},{"key":"59888_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/MOU.0000000000000089","volume":"24","author":"SP Porten","year":"2014","unstructured":"Porten, S. P., Willis, D. & Kamat, A. M. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr. Opin. Urol. 24, 517\u2013523 (2014).","journal-title":"Curr. Opin. Urol."},{"key":"59888_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MOU.0b013e328363e415","volume":"23","author":"DL Willis","year":"2013","unstructured":"Willis, D. L., Porten, S. P. & Kamat, A. M. Should histologic variants alter definitive treatment of bladder cancer?. Curr. Opin. Urol. 23, 435\u2013443 (2013).","journal-title":"Curr. Opin. Urol."},{"key":"59888_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JU.0000000000001325","volume":"205","author":"A Hajiran","year":"2021","unstructured":"Hajiran, A. et al. Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J. Urol. 205, 100\u2013108 (2021).","journal-title":"J. Urol."},{"key":"59888_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","volume":"77","author":"JA Witjes","year":"2020","unstructured":"Witjes, J. A. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer\u2014an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO Guidelines Committees. Eur. Urol. 77, 223\u2013250 (2020).","journal-title":"Eur. Urol."},{"key":"59888_CR7","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1002\/cncr.30907","volume":"123","author":"MW Vetterlein","year":"2017","unstructured":"Vetterlein, M. W. et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer 123, 4346\u20134355 (2017).","journal-title":"Cancer"},{"key":"59888_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00847-7","author":"CC Guo","year":"2024","unstructured":"Guo, C. C. et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat. Rev. Urol. https:\/\/doi.org\/10.1038\/s41585-023-00847-7 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"59888_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"59888_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"59888_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","volume":"85","author":"DN Palsgrove","year":"2019","unstructured":"Palsgrove, D. N. et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum. Pathol. 85, 1\u20139 (2019).","journal-title":"Hum. Pathol."},{"key":"59888_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00428-016-2001-2","volume":"469","author":"D Nguyen","year":"2016","unstructured":"Nguyen, D. et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 469, 427\u2013434 (2016).","journal-title":"Virchows Arch."},{"key":"59888_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00428-017-2164-5","volume":"471","author":"MDC Rodriguez Pena","year":"2017","unstructured":"Rodriguez Pena, M. D. C. et al. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch. 471, 761\u2013767 (2017).","journal-title":"Virchows Arch."},{"key":"59888_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng.3503","volume":"48","author":"HA Al-Ahmadie","year":"2016","unstructured":"Al-Ahmadie, H. A. et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat. Genet 48, 356\u2013358 (2016).","journal-title":"Nat. Genet"},{"key":"59888_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41379-021-00776-z","volume":"34","author":"L Cheng","year":"2021","unstructured":"Cheng, L. et al. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. Mod. Pathol. 34, 1384\u20131391 (2021).","journal-title":"Mod. Pathol."},{"key":"59888_CR16","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","volume":"39","author":"V Weyerer","year":"2021","unstructured":"Weyerer, V. et al. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J. Urol. 39, 4011\u20134019 (2021).","journal-title":"World J. Urol."},{"key":"59888_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/his.13958","volume":"75","author":"V Weyerer","year":"2019","unstructured":"Weyerer, V. et al. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology 75, 865\u2013875 (2019).","journal-title":"Histopathology"},{"key":"59888_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24606","volume":"36","author":"N Setti Boubaker","year":"2022","unstructured":"Setti Boubaker, N. et al. An insight into the diagnostic and prognostic value of HOX A13\u2019s expression in non-muscle invasive bladder cancer. J. Clin. Lab Anal. 36, e24606 (2022).","journal-title":"J. Clin. Lab Anal."},{"key":"59888_CR19","first-page":"833","volume":"20","author":"L Marra","year":"2013","unstructured":"Marra, L. et al. Deregulation of HOX B13 expression in urinary bladder cancer progression. Curr. Med. Chem. 20, 833\u2013839 (2013).","journal-title":"Curr. Med. Chem."},{"key":"59888_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/stem.140281","volume":"14","author":"HJ Lawrence","year":"1996","unstructured":"Lawrence, H. J., Sauvageau, G., Humphries, R. K. & Largman, C. The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells 14, 281\u2013291 (1996).","journal-title":"Stem Cells"},{"key":"59888_CR21","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.1038\/sj.onc.1210760","volume":"26","author":"B Argiropoulos","year":"2007","unstructured":"Argiropoulos, B. & Humphries, R. K. Hox genes in hematopoiesis and leukemogenesis. Oncogene 26, 6766\u20136776 (2007).","journal-title":"Oncogene"},{"key":"59888_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/leu.2012.356","volume":"27","author":"RA Alharbi","year":"2013","unstructured":"Alharbi, R. A., Pettengell, R., Pandha, H. S. & Morgan, R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 27, 1000\u20131008 (2013).","journal-title":"Leukemia"},{"key":"59888_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0092-8674(02)00697-9","volume":"109","author":"J Antonchuk","year":"2002","unstructured":"Antonchuk, J., Sauvageau, G. & Humphries, R. K. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 109, 39\u201345 (2002).","journal-title":"Cell"},{"key":"59888_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1101\/gad.9.14.1753","volume":"9","author":"G Sauvageau","year":"1995","unstructured":"Sauvageau, G. et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev. 9, 1753\u20131765 (1995).","journal-title":"Genes Dev."},{"key":"59888_CR25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2004-04-1583","volume":"105","author":"NA Fischbach","year":"2005","unstructured":"Fischbach, N. A. et al. HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood 105, 1456\u20131466 (2005).","journal-title":"Blood"},{"key":"59888_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.exphem.2006.10.014","volume":"35","author":"KH Ko","year":"2007","unstructured":"Ko, K. H. et al. Hoxb3 deficiency impairs B lymphopoiesis in mouse bone marrow. Exp. Hematol. 35, 465\u2013475 (2007).","journal-title":"Exp. Hematol."},{"key":"59888_CR27","doi-asserted-by":"publisher","first-page":"104594","DOI":"10.1016\/j.cellimm.2022.104594","volume":"380","author":"TF Tang","year":"2022","unstructured":"Tang, T. F. et al. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis. Cell Immunol. 380, 104594 (2022).","journal-title":"Cell Immunol."},{"key":"59888_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115\u2013119 (2011).","journal-title":"Nature"},{"key":"59888_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","volume":"97","author":"G Jego","year":"2001","unstructured":"Jego, G., Bataille, R. & Pellat-Deceunynck, C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 97, 1817\u20131822 (2001).","journal-title":"Blood"},{"key":"59888_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduct. Target Ther. 7, 346 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"59888_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"YH Huang","year":"2018","unstructured":"Huang, Y. H. et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 32, 915\u2013928 (2018).","journal-title":"Genes Dev."},{"key":"59888_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289\u2013297 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"59888_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18916-5","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat. Commun. 11, 5077 (2020).","journal-title":"Nat. Commun."},{"key":"59888_CR34","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1158\/1078-0432.CCR-20-4796","volume":"27","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. Clin. Cancer Res. 27, 6265\u20136278 (2021).","journal-title":"Clin. Cancer Res."},{"key":"59888_CR35","doi-asserted-by":"crossref","unstructured":"Abugomaa, A., Elbadawy, M., Yamawaki, H., Usui, T. & Sasaki, K. Emerging roles of cancer stem cells in bladder cancer progression, tumorigenesis, and resistance to chemotherapy: a potential therapeutic target for bladder cancer. Cells 9, 235 (2020).","DOI":"10.3390\/cells9010235"},{"key":"59888_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.stemcr.2017.07.004","volume":"9","author":"F Zhu","year":"2017","unstructured":"Zhu, F. et al. SOX2 is a marker for stem-like tumor cells in bladder cancer. Stem Cell Rep. 9, 429\u2013437 (2017).","journal-title":"Stem Cell Rep."},{"key":"59888_CR37","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1093\/bioinformatics\/bty452","volume":"34","author":"C Suphavilai","year":"2018","unstructured":"Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34, 3907\u20133914 (2018).","journal-title":"Bioinformatics"},{"key":"59888_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.canlet.2017.11.015","volume":"414","author":"R Cao","year":"2018","unstructured":"Cao, R. et al. TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARgamma-SIRT1 feedback loop in human bladder cancer cells. Cancer Lett. 414, 278\u2013293 (2018).","journal-title":"Cancer Lett."},{"key":"59888_CR39","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/0008-5472.CAN-03-2028","volume":"64","author":"C Jones","year":"2004","unstructured":"Jones, C. et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 64, 3037\u20133045 (2004).","journal-title":"Cancer Res."},{"key":"59888_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","volume":"611","author":"A Canellas-Socias","year":"2022","unstructured":"Canellas-Socias, A. et al. Metastatic recurrence in colorectal cancer arises from residual EMP1(+) cells. Nature 611, 603\u2013613 (2022).","journal-title":"Nature"},{"key":"59888_CR41","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1002\/cam4.5637","volume":"12","author":"Q Zeng","year":"2023","unstructured":"Zeng, Q. et al. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis. Cancer Med. 12, 9024\u20139040 (2023).","journal-title":"Cancer Med."},{"key":"59888_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.canlet.2015.08.019","volume":"369","author":"M Kuwada","year":"2015","unstructured":"Kuwada, M. et al. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer. Cancer Lett. 369, 212\u2013221 (2015).","journal-title":"Cancer Lett."},{"key":"59888_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13046-020-01690-z","volume":"39","author":"Q Tang","year":"2020","unstructured":"Tang, Q. et al. TM4SF1 promotes EMT and cancer stemness via the Wnt\/beta-catenin\/SOX2 pathway in colorectal cancer. J. Exp. Clin. Cancer Res. 39, 232 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"59888_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep45895","volume":"7","author":"JC Yang","year":"2017","unstructured":"Yang, J. C. et al. TM4SF1 promotes metastasis of pancreatic cancer via regulating the expression of DDR1. Sci. Rep. 7, 45895 (2017).","journal-title":"Sci. Rep."},{"key":"59888_CR45","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"59888_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes, C. J. et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J. Clin. Oncol. 41, 22\u201331 (2023).","journal-title":"J. Clin. Oncol."},{"key":"59888_CR47","doi-asserted-by":"publisher","unstructured":"Shalek, A. K. & Benson, M. Single-cell analyses to tailor treatments. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan4730 (2017).","DOI":"10.1126\/scitranslmed.aan4730"},{"key":"59888_CR48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1476-5586(03)80018-0","volume":"5","author":"S Banerjee","year":"2003","unstructured":"Banerjee, S. et al. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5, 63\u201373 (2003).","journal-title":"Neoplasia"},{"key":"59888_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2010.44","volume":"7","author":"AK Karam","year":"2010","unstructured":"Karam, A. K. & Karlan, B. Y. Ovarian cancer: the duplicity of CA125 measurement. Nat. Rev. Clin. Oncol. 7, 335\u2013339 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"59888_CR50","doi-asserted-by":"publisher","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","volume":"1875","author":"M Zhang","year":"2021","unstructured":"Zhang, M., Cheng, S., Jin, Y., Zhao, Y. & Wang, Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim. Biophys. Acta Rev. Cancer 1875, 188503 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"59888_CR51","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1158\/0008-5472.CAN-20-3982","volume":"81","author":"J Janjanam","year":"2021","unstructured":"Janjanam, J. et al. Matricellular protein WISP2 is an endogenous inhibitor of collagen linearization and cancer metastasis. Cancer Res. 81, 5666\u20135677 (2021).","journal-title":"Cancer Res."},{"key":"59888_CR52","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump, A. et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279, 9190\u20139198 (2004).","journal-title":"J. Biol. Chem."},{"key":"59888_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep01870","volume":"3","author":"SH Chen","year":"2013","unstructured":"Chen, S. H., Hung, W. C., Wang, P., Paul, C. & Konstantopoulos, K. Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci. Rep. 3, 1870 (2013).","journal-title":"Sci. Rep."},{"key":"59888_CR54","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ajpath.2022.12.005","volume":"193","author":"T Yamashita","year":"2023","unstructured":"Yamashita, T. et al. Cancer antigen 125 expression enhances the gemcitabine\/cisplatin-resistant tumor microenvironment in bladder cancer. Am. J. Pathol. 193, 350\u2013361 (2023).","journal-title":"Am. J. Pathol."},{"key":"59888_CR55","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.18632\/oncotarget.6819","volume":"7","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget 7, 5943\u20135956 (2016).","journal-title":"Oncotarget"},{"key":"59888_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2021.08.027","volume":"523","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Wei, Q., Dong, D. & Ren, L. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin. Chim. Acta 523, 19\u201325 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"59888_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05067-2","volume":"13","author":"S Hou","year":"2022","unstructured":"Hou, S. et al. TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin alpha6. Cell Death Dis. 13, 609 (2022).","journal-title":"Cell Death Dis."},{"key":"59888_CR58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-022-01177-7","volume":"7","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells. Signal Transduct. Target Ther. 7, 350 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"59888_CR59","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.immuni.2020.09.015","volume":"53","author":"TK Hughes","year":"2020","unstructured":"Hughes, T. K. et al. Second-strand synthesis-based massively parallel scRNA-Seq reveals cellular states and molecular features of human inflammatory skin pathologies. Immunity 53, 878\u2013894.e7 (2020).","journal-title":"Immunity"},{"key":"59888_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song, H. et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat. Commun. 13, 141 (2022).","journal-title":"Nat. Commun."},{"key":"59888_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59888_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"59888_CR63","unstructured":"Suphavilai, C. C. S. et al. CaDRReS-Sc. https:\/\/github.com\/CSB5\/CaDRReS-Sc (2021)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59888-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59888-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59888-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:02:07Z","timestamp":1750136527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59888-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59888"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59888-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. and F.H. are inventors on a patent application related to the CAR T cell technology described in this manuscript (\u201cTM4SF1 CAR CELLS AND METHODS OF USE THEREOF\u201d, U.S. Patent Application No. 63\/649,157, U.S. Patent Application No. 63\/649,821). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5312"}}